News
SCAI Therapeutics, ‘SCAI-001, IMD CsA1’ Domestic phase 2 “IND approval” for dry eye syndrome
Author
SCAI Therapeutics
Date
2022-12-09 22:52
Views
1070
SCAI Therapeutics announced on December 9 that it had received approval for a phase 2 clinical trial plan for SCAI-001, a candidate substance for the treatment of dry eye syndrome, from the Ministry of Food and Drug Safety in Korea. SCAI Therapeutics plans to start phase 2 clinical trials in January of 2023.
SCAI-001 is an IMD (Incrementally Modified Drug) that applies MOASIS™, SCAI’s bioavailability improvement technology, to cyclosporine A. In animal models, SCAI used 1/5 to 2/5 lower dose than conventional drugs and reduced excipients by 90% but confirmed the excellent tear production and corneal epithelial cell healing effect of SCAI-001.
SCAI Therapeutics expects to improve signs and syndromes of dry eye syndrome and relieve eye pain caused by conventional treatments.
SCAI Therapeutics expects that if SCAI-001 succeeds in development, it will not only significantly improve the compliance of patients with dry eye syndrome but also realize PoC (Proof of Concept) in the human body of its MOASIS™ technology.
Chul Hwan Kim, CEO of SCAI Therapeutics, said, “We plan to administer SCAI-001 to patients early next year, and apply MOASIS™ technology to apply for an additional clinical trial plan for a candidate substance that changes the administration route from macular degeneration treatment
SCAI-001 is an IMD (Incrementally Modified Drug) that applies MOASIS™, SCAI’s bioavailability improvement technology, to cyclosporine A. In animal models, SCAI used 1/5 to 2/5 lower dose than conventional drugs and reduced excipients by 90% but confirmed the excellent tear production and corneal epithelial cell healing effect of SCAI-001.
SCAI Therapeutics expects to improve signs and syndromes of dry eye syndrome and relieve eye pain caused by conventional treatments.
SCAI Therapeutics expects that if SCAI-001 succeeds in development, it will not only significantly improve the compliance of patients with dry eye syndrome but also realize PoC (Proof of Concept) in the human body of its MOASIS™ technology.
Chul Hwan Kim, CEO of SCAI Therapeutics, said, “We plan to administer SCAI-001 to patients early next year, and apply MOASIS™ technology to apply for an additional clinical trial plan for a candidate substance that changes the administration route from macular degeneration treatment